Breaking News

HRSA Sends Merck 340B Contract Pharmacy Cease and Desist Letter, Agency’s First in Seven Months

HRSA told Merck today the company's conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop or Merck could face civil monetary penalties.

The federal government told drug manufacturer Merck today its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop, or the company could face penalties of up to $6,323 per each

Read More »

Breaking News

HRSA Picks Federal HIV/AIDS Policy Specialist Emeka Egwim To Be its Next 340B Program Director

PHS Lt. Cmdr. Emeka Edwim is the new Director of HRSA's Office of Pharmacy Affairs, the HRSA unit that runs the 340B drug pricing program.

Emeka Egwim, a federal government HIV/AIDS policy specialist who also has served in the Medicaid Drug Rebate Program, is the new head of the federal 340B Drug Pricing Program.

Please Login or Become a Paid Subscriber

Read More »

Breaking News

Federal Judge Vacates HRSA’s Finding that AstraZeneca’s 340B Contract Pharmacy Policy Is Illegal

A federal district judge today struck down and vacated HRSA's May 2021 finding that AstraZeneca's 340B contract pharmacy policy violates the 340B statute.

A federal district judge in Wilmington, Del., today struck down and vacated the federal government’s finding that drug maker AstraZeneca’s conditions on 340B pricing when covered entities uses contract pharmacies violates the 340B statute.

Please Login

Read More »

Breaking News

Hospital Group Leader Says “We’re Prepared to Go” in Direction of Federal 340B Contract Pharmacy Legislation

If the path to solving the 340B contract pharmacy dispute runs through Congress, "we're prepared to go in that direction,” 340B Health President and CEO Maureen Testoni said today.

For the first time since the 340B contract pharmacy impasse started over a year and half ago, the leader of an influential hospital group said publicly today her association is prepared to move in the direction of a federal legislative

Read More »

Breaking News

BMS Clamps Down on 340B Contract Pharmacy for Most of its Drugs but Expands 340B Access to its Controversial Myeloma Meds Program

BMS yesterday imposed restrictions on 340B pricing on most of its covered outpatient drugs, while liberalizing its policy on access to 340B pricing on its expensive cancer drugs Revlimid, Pomalyst, and Thalomid.

Bristol Myers Squibb (BMS) yesterday became the 12th drug manufacturer to impose restrictions on 340B pricing when hospitals and grantee covered entities contract with pharmacies to dispense drugs to patients.

Please Login or Become a Paid

Read More »

Breaking News

Breaking News: AbbVie Becomes 11th Drug Maker to Restrict 340B Contract Pharmacy. Feds Appeal Rulings in Lilly, Novo Nordisk, and Sanofi Cases.

AbbVie is the 11th pharmaceutical maker to impose limits on 340B contract pharmacy.

AbbVie today announced conditions on 340B pricing when hospitals’ contract pharmacies dispense medicines to patients. The federal government has filed notices of appeal in Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics’ 340B contract pharmacy lawsuits.

Read More »

Breaking News

Breaking News: Feds Appeal Rulings in Novartis and United Therapeutics 340B Contract Pharmacy Cases

The federal government yesterday asked the federal appeals court in Washington, D.C., to review a lower court's Nov. 5 joint ruling in Novartis and United Therapeutics' 340B contract pharmacy lawsuits.

The federal government late yesterday filed notice that it is appealing a federal judge’s joint ruling in two cases last month that halted enforcement actions against two drug companies that deny 340B pricing when hospitals and other health care providers

Read More »

Breaking News

Breaking News: Amgen Announces 340B Contract Pharmacy Limits for Hospitals

Amgen this morning became the 10th pharmaceutical manufacturer to announce conditions on 340B pricing when contract pharmacies dispense medicines to patients.

Biopharmaceutical manufacturer Amgen this morning became the 10th pharmaceutical to announce conditions on 340B pricing when contract pharmacies dispense medicines to patients.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Breaking News

Breaking: Another Federal Judge Issues a Mixed Opinion in 340B Contract Pharmacy Litigation, this Time in Novartis and United Therapeutics’ Cases

U.S. District Judge Dabney Friedrich last night issued the second court ruling of the day involving drug manufacturers’ denials of and limitations on 340B pricing when covered entities use contract pharmacies.

A federal district judge last night issued the second court ruling of the day involving drug manufacturers’ denials of and limitations on 340B pricing when covered entities use contract pharmacies. Like the day’s earlier ruling, this one too was mixed,

Read More »

Breaking News

Breaking: Federal Judge Hands Down Mixed Opinion in Sanofi and Novo Nordisk’s 340B Contract Pharmacy Lawsuits

U.S. Chief District Judge Freda Wolfson ruled today that Sanofi and Novo Nordisk's 340B contract pharmacy policies violate the 340B statute. But she declined to decide whether the 340B statute permits covered entities to use multiple or unlimited contract pharmacies.

A federal district judge this afternoon upheld the federal government’s finding that drug manufacturers Sanofi and Novo Nordisk cannot unilaterally impose restrictions on offers of 340B pricing to covered entities and that their policies must cease. But she also vacated

Read More »
Generic selectors
Exact matches only
Search in title
Search in content